Clinical Trials

The studies listed on this page are updated daily from Clinicaltrials.gov. The list includes clinical studies conducted at Children's National Medical Center/Children's Research Institute that are open for recruitment.

You can view this same search on the ClinicalTrials.gov website.

List updated 05/23/2017 - 07:03.

Displaying 1 - 250 of 361 results.

Clinical Trial ClinicalTrials.gov Identifier and Link
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
Conditions:   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Lymphoproliferative Disorder
Interventions:   Drug: EBV CTL's;   Other: Peripheral Blood Donor
Sponsors:   New York Medical College;   Children's Research Institute;   Baylor College of Medicine;   M.D. Anderson Cancer Center;   University of Michigan;   University of Utah;   Beckman Research Institute;   Ohio University;   Johns Hopkins University
Recruiting - verified February 2014
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic...
Condition:   Epilepsy, Partial Seizures
Intervention:   Drug: Pregabalin
Sponsors:   Pfizer;   Pfizer
Recruiting - verified October 2013
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Condition:   Medulloblastoma
Interventions:   Radiation: Craniospinal Irradiation with boost to the primary tumor site;   Drug: Cyclophosphamide;   Drug: Cisplatin;   Drug: Vincristine;   Drug: Vismodegib;   Drug: Pemetrexed;   Drug: Gemcitabine;   Other: Aerobic Training;   Other: Neurocognitive Remediation
Sponsors:   St. Jude Children's Research Hospital;   Genentech, Inc.
Recruiting - verified January 2015
A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase ...
Conditions:   Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
Intervention:   Drug: pegcrisantaspase
Sponsor:   Jazz Pharmaceuticals
Recruiting - verified December 2014
A Extension Study of Udenafil in Adolescents
Condition:   Functional Single Ventricle Heart Disease
Intervention:   Drug: Udenafil
Sponsors:   Mezzion Pharma Co. Ltd;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified January 2017
A Feasibility Study of SAHA Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Conditions:   Untreated Childhood Medulloblastoma;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions:   Drug: vorinostat;   Drug: isotretinoin;   Drug: vincristine sulfate;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: thiotepa;   Procedure: peripheral blood stem cell transplantation;   Radiation: 3-dimensional conformal radiation therapy;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified July 2013
A Multi-Center Randomized Controlled Trial of Mentoring to Prevent Youth Violence
Condition:   Violence Prevention
Intervention:   Behavioral: Take Charge 2
Sponsors:   Johns Hopkins University;   Johns Hopkins University
Not yet recruiting - verified January 2013
A Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients
Condition:   Acute Pain
Interventions:   Drug: IV Acetaminophen;   Other: Normal Saline as Placebo
Sponsors:   Cadence Pharmaceuticals;   Cadence Pharmaceuticals;   Pharsight;   Quanticate
Recruiting - verified October 2012
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions:   Hematological Malignancies;   Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders;   Hurler Syndrome (MPS I);   Krabbe Disease (Globoid Leukodystrophy);   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors:   Center for International Blood and Marrow Transplant Research;   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
Recruiting - verified October 2013
A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset Facioscapulohumeral Muscular Dystrophy
Condition:   Facioscapulohumeral Muscular Dystrophy
Intervention:  
Sponsors:   Cooperative International Neuromuscular Research Group;   Cooperative International Neuromuscular Research Group;   FSH Society;   FSHD Global Research Foundation;   Muscular Dystrophy Canada
Recruiting - verified September 2013
A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy
Condition:   Narcolepsy With Cataplexy
Intervention:   Drug: Xyrem
Sponsor:   Jazz Pharmaceuticals
Recruiting - verified October 2014
A Multiple Ascending Dose-Finding Pharmacokinetic and Pharmacodynamic Study of a Novel Antiviral Drug in Infants With Neonatal Herpes Simplex Virus (HSV)
Condition:   Herpes Simplex Virus
Interventions:   Drug: Novel Antiviral Drug;   Drug: Placebo
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham
Not yet recruiting - verified March 2013
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Conditions:   Rhabdoid Tumors;   INI1-negative Tumors;   Synovial Sarcoma;   Malignant Rhabdoid Tumor of Ovary
Intervention:   Drug: Tazemetostat
Sponsor:   Epizyme, Inc.
Recruiting - verified February 2016
A Phase 3 Study of UX003 rhGUS Enzyme Replacement Therapy in Patients With MPS 7
Conditions:   MPS 7;   Sly Syndrome;   Mucopolysaccharidosis;   MPS VII
Intervention:   Drug: UX003
Sponsor:   Ultragenyx Pharmaceutical Inc
Not yet recruiting - verified August 2014
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Conditions:   Medulloblastoma,;   Rhabdomyosarcoma,;   Neuroblastoma,;   Hepatoblastoma,;   High Grade Glioma,;   Astrocytoma
Intervention:   Drug: LDE225
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified September 2013
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood
Interventions:   Drug: Azacitidine;   Drug: Fludarabine;   Drug: Cytarabine
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   Gateway for Cancer Research;   USC/Norris Comprehensive Cancer Center
Not yet recruiting - verified May 2013
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
Conditions:   Pediatric Cancer;   Solid Tumors
Interventions:   Device: Magnetic resonance high intensity focused ultrasound;   Drug: Lyso-thermosensitive liposomal doxorubicin
Sponsor:   AeRang Kim
Not yet recruiting - verified August 2015
A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids
Condition:   Duchenne Muscular Dystrophy (DMD)
Interventions:   Drug: Idebenone 150 mg film-coated tablets;   Drug: placebo
Sponsor:   Santhera Pharmaceuticals
Recruiting - verified March 2017
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Conditions:   Acute Lymphoblastic Leukemia;   Precursor B-Cell Lymphoblastic Leukemia;   Precursor T-Cell Lymphoblastic Leukemia
Interventions:   Drug: Decitabine;   Drug: Vorinostat;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Mitoxantrone;   Drug: Pegaspargase;   Drug: Methotrexate
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified March 2013
A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
Condition:   Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions:   Drug: RAD001;   Drug: Placebo
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2013
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Condition:   Neurofibromatosis Type 1
Interventions:   Drug: Lovastatin ™;   Device: placebo
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Children's Hospital Boston;   Children's Hospital Philadelphia;   Children's Research Institute;   Children's Hospital Medical Center, Cincinnati;   National Cancer Institute (NCI);   University of Chicago;   University of Utah;   Washington University School of Medicine;   The Children's Hospital at Westmead;   University of Texas Southwestern Medical Center
Recruiting - verified April 2013
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
Condition:   Partial Onset Seizures
Interventions:   Drug: Pregabalin Dose Level 1;   Drug: Pregabalin Dose Level 2;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified May 2015
A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)
Conditions:   NF1;   Congenital Pseudarthrosis of Tibia
Interventions:   Device: INFUSE Bone Graft (BMP-2);   Procedure: Control Group
Sponsors:   University of Alabama at Birmingham;   The Children's Tumor Foundation;   Medtronic
Not yet recruiting - verified March 2016
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
Condition:   Soft Tissue Sarcoma
Interventions:   Drug: Olaratumab;   Drug: Gemcitabine;   Drug: Docetaxel;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2016
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Condition:   Neoplasm Metastasis
Interventions:   Drug: Olaratumab;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Irinotecan;   Drug: Ifosfamide
Sponsor:   Eli Lilly and Company
Recruiting - verified April 2017
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood;   Hodgkin's Disease;   Non-Hodgkin's Lymphoma
Interventions:   Drug: Panobinostat;   Drug: Cytarabine;   Drug: Panobinostat
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Novartis
Recruiting - verified December 2014
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
Conditions:   Pediatric Solid Tumor;   Refractory Tumor;   Recurrent Tumor;   CNS Malignancies
Intervention:   Drug: Ramucirumab
Sponsors:   Eli Lilly and Company;   Children's Oncology Group
Not yet recruiting - verified September 2015
A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders (UCDs)
Condition:   Urea Cycle Disorder
Intervention:   Drug: RAVICTI
Sponsor:   Hyperion Therapeutics, Inc.
Not yet recruiting - verified September 2014
A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn
Condition:   Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions:   Drug: placebo;   Drug: iv sildenafil
Sponsor:   Pfizer
Recruiting - verified November 2013
A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST
Conditions:   Malignant Peripheral Nerve Sheath Tumors (MPNST);   Sarcoma
Interventions:   Drug: ganetespib;   Drug: Sirolimus
Sponsors:   Sarcoma Alliance for Research through Collaboration;   Synta Pharmaceuticals Corp.;   Department of Defense
Recruiting - verified November 2014
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Lymphoblastic Lymphoma;   Peripheral T-cell Lymphoma
Interventions:   Drug: Temsirolimus;   Drug: Etoposide;   Drug: Etoposide phosphate;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Hydrocortisone;   Drug: Cytarabine
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Pfizer
Recruiting - verified March 2015
Abatacept as GVHD Prophylaxis Phase 2
Conditions:   Graft vs Host Disease;   Malignancy
Interventions:   Drug: Abatacept;   Drug: placebo
Sponsor:   Seattle Children's Hospital
Recruiting - verified September 2014
Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
Conditions:   Sickle Cell Disease;   Graft Versus Host Disease
Interventions:   Drug: Premedication;   Drug: Immunosuppression;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Calcineurin inhibitor;   Drug: Methotrexate;   Drug: Abatacept;   Procedure: Marrow infusion
Sponsor:   Monica Bhatia
Recruiting - verified August 2016
Academic Achievement in Children With Asthma
Condition:   Asthma
Intervention:   Other: Survey
Sponsor:   Children's Research Institute
Not yet recruiting - verified August 2014
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Conditions:   Central Nervous System Tumor, Pediatric;   Chemotherapy-induced Nausea and Vomiting;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Procedure: Real Acupressure Band;   Procedure: Placebo Acupressure Band
Sponsors:   University of South Florida;   National Cancer Institute (NCI)
Recruiting - verified December 2013
Adult Congenital Heart Disease Registry (QuERI)
Conditions:   Pulmonary Arterial Hypertension;   Congenital Heart Disease
Intervention:   Other: observational
Sponsors:   Actelion;   Canadian Heart Research Centre
Recruiting - verified January 2014
ADVANCE ASO AMPLATZER™ Atrial Septal Occluder Post Market Surveillance Study
Condition:   Atrial Septal Defect Secundum
Intervention:   Device: atrial septal occluder
Sponsor:   St. Jude Medical
Recruiting - verified April 2015
Age of Blood in Children in Pediatric Intensive Care Units
Condition:   Anemia
Intervention:   Biological: Short storage RBC age
Sponsors:   Washington University School of Medicine;   National Heart, Lung, and Blood Institute (NHLBI);   Canadian Institutes of Health Research (CIHR);   Ministere de la Sante et des Services Sociaux (MSSS)
Not yet recruiting - verified October 2013
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Conditions:   Childhood Hepatoblastoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions:   Drug: alisertib;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013
Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
Conditions:   EBV;   CMV;   Adenovirus
Interventions:   Drug: CTL for CMV seropositive donors;   Drug: CTL for CMV naïve donors
Sponsors:   Children's Research Institute;   Catherine Bollard
Not yet recruiting - verified September 2013
Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Conditions:   EBV Infection;   CMV Infection;   Adenoviral Infection
Intervention:   Biological: Trivirus-Specific CTLs
Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   Houston Methodist Hospital;   Children's Hospital Los Angeles;   Duke University;   Hackensack University Medical Center;   New York Medical College;   University of Texas Southwestern Medical Center;   Children's Research Institute;   All Children’s Hospital Johns Hopkins Medicine
Available - verified March 2014
Allogeneic Virus-specific T Cell Lines (VSTs)
Condition:   Viral Infections After HSCT
Intervention:   Biological: VSTs
Sponsor:   Catherine Bollard
Recruiting - verified July 2015
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Condition:   Human Immunodeficiency Virus (HIV)
Intervention:   Drug: Maraviroc
Sponsors:   ViiV Healthcare;   Pfizer
Recruiting - verified October 2014
An Open-label Phase 2 Study of UX007 (Triheptanoin) in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Conditions:   Long-chain Fatty Acid Oxidation Disorders (LC-FAOD);   Carnitine Palmitoyltransferase (CPT II) Deficiency;   Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency;   Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency;   Trifunctional Protein (TFP) Deficiency
Intervention:   Drug: UX007
Sponsor:   Ultragenyx Pharmaceutical Inc
Recruiting - verified March 2014
An Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia
Condition:   Hyperphosphatemia
Interventions:   Drug: PA21 (Velphoro®);   Drug: Calcium Acetate (Phoslyra®)
Sponsor:   Vifor Fresenius Medical Care Renal Pharma
Recruiting - verified January 2017
Analyses of Human Samples Collected in Clinical Trials
Conditions:   Leukemia, Myeloid;   Neoplasm Metastasis;   Leukemia, Lymphoid;   Prostate Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified July 2014
Assessing Inherited Markers of Metabolic Syndrome in the Young
Conditions:   Metabolic Syndrome;   Diabetes Mellitus, Type 2;   Obesity
Intervention:  
Sponsors:   Children's Research Institute;   Children's Research Institute;   National Institutes of Health (NIH);   Howard University;   University of Massachusetts, Worcester;   East Carolina University
Recruiting - verified March 2011
ATHN 2: Factor Switching Study
Condition:   Hemophilia
Interventions:   Biological: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013;   Biological: Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
Sponsor:   American Thrombosis and Hemostasis Network
Recruiting - verified November 2015
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
Conditions:   Acute Leukemia of Ambiguous Lineage;   Childhood B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia
Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified March 2017
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
Conditions:   Neurofibromatosis 1;   Neurofibromatosis Type 1;   NF 1;   Neurofibroma, Plexiform
Intervention:   Drug: AZD6244 hyd sulfate
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2012
BBD Longitudinal Study of Osteogenesis Imperfecta
Condition:   Osteogenesis Imperfecta
Intervention:  
Sponsors:   Baylor College of Medicine;   Shriners Hospitals for Children;   Hospital for Special Surgery, New York;   Children's Research Institute;   Hugo W. Moser Research Institute at Kennedy Krieger, Inc.;   University of California, Los Angeles;   Oregon Health and Science University
Not yet recruiting - verified April 2015
Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping
Condition:   Becker Muscular Dystrophy
Intervention:  
Sponsors:   Cooperative International Neuromuscular Research Group;   Cooperative International Neuromuscular Research Group
Recruiting - verified September 2013
Bedside Lung Ultrasound in Young Children Presenting to the Emergency Department (ED) With Wheezing
Conditions:   Wheezing;   Bronchiolitis
Intervention:  
Sponsors:   Children's Research Institute;   Children's Research Institute
Recruiting - verified October 2012
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Condition:   Neuroblastoma
Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: nucleic acid amplification;   Genetic: polymerase chain reaction;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: cytology specimen collection procedure;   Other: flow cytometry;   Procedure: biopsy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified November 2012
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
Conditions:   Adult B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified June 2015
BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
Conditions:   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: PARP inhibitor BMN-673;   Drug: temozolomide;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2014
Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease
Condition:   Sickle Cell Disease
Intervention:   Other: Biological: Bone Marrow Transplant
Sponsors:   University of Pittsburgh;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2014
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
Condition:   Sickle Cell Disease
Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: r-ATG;   Procedure: Bone Marrow Transplant;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Standard of Care
Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   Dana-Farber Cancer Institute
Not yet recruiting - verified May 2016
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Lymphoblastic Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia
Interventions:   Drug: asparaginase;   Drug: doxorubicin hydrochloride;   Drug: therapeutic hydrocortisone;   Drug: liposomal vincristine sulfate;   Drug: cytarabine;   Drug: prednisone;   Drug: bortezomib;   Drug: pegaspargase;   Drug: methotrexate;   Drug: etoposide phosphate;   Drug: cyclophosphamide;   Biological: filgrastim;   Drug: leucovorin calcium;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified October 2013
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions:   Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: mitoxantrone hydrochloride;   Drug: sorafenib tosylate;   Drug: cytarabine;   Drug: etoposide;   Drug: bortezomib;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: quality-of-life assessment
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified October 2014
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
Conditions:   Cognitive/Functional Effects;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment
Interventions:   Genetic: microarray analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: cognitive assessment;   Procedure: diffusion tensor imaging;   Procedure: management of therapy complications;   Procedure: psychosocial assessment and care
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2011
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma
Conditions:   Stage II Childhood Hodgkin Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage IV Childhood Hodgkin Lymphoma
Interventions:   Drug: Doxorubicin Hydrochloride;   Biological: Bleomycin Sulfate;   Drug: Vincristine Sulfate;   Drug: Etoposide;   Drug: Prednisone;   Drug: Cyclophosphamide;   Drug: Brentuximab Vedotin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Laboratory Biomarker Analysis
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified March 2015
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions:   Recurrent Adult Hodgkin Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma
Interventions:   Drug: brentuximab vedotin;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified January 2014
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Conditions:   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma
Interventions:   Drug: Brentuximab Vedotin;   Drug: Crizotinib;   Drug: Dexamethasone;   Drug: Ifosfamide;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified September 2014
Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer
Condition:   Cancer
Intervention:   Behavioral: FAmily CEntered Advance Care Planning for Teens with Cancer
Sponsors:   Maureen Lyon;   St. Jude Children's Research Hospital;   Akron Children's Hospital;   National Institute of Nursing Research (NINR)
Not yet recruiting - verified February 2016
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Conditions:   Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions:   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: cisplatin;   Drug: etoposide;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Radiation: external beam radiation therapy;   Drug: busulfan;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Biological: filgrastim;   Drug: mesna
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified October 2014
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +)
Conditions:   NF1;   Neurofibromatosis;   Plexiform Neurofibromas
Intervention:   Drug: Cabozantinib
Sponsor:   University of Alabama at Birmingham
Not yet recruiting - verified March 2014
Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Conditions:   Recurrent Melanoma;   Recurrent Thyroid Cancer;   Thyroid Gland Medullary Carcinoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: cabozantinib-s-malate;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified June 2013
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy
Conditions:   Fungal Infection;   Leukemia;   Neutropenia
Interventions:   Drug: caspofungin acetate;   Drug: fluconazole
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2013
Cause of Focal Segmental Glomerulosclerosis
Conditions:   AIDS Associated Nephropathy;   Focal Glomerulosclerosis;   HIV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2013
Cellular Immunotherapy for Viral Induced Cancer
Conditions:   Hodgkin Lymphoma;   Lymphoma, Large B-Cell, Diffuse;   Post-transplant Lymphoproliferative Disorder
Intervention:   Biological: CMD-003
Sponsor:   Cell Medica Ltd
Not yet recruiting - verified May 2016
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
Conditions:   Lymphoma, Extranodal NK-T-Cell;   EBV
Intervention:   Biological: CMD-003
Sponsor:   Cell Medica Ltd
Not yet recruiting - verified November 2013
Changes in Sleep Patterns and Stress in Infants Entering Child Care
Condition:   Sudden Infant Death Syndrome
Intervention:  
Sponsors:   Children's Research Institute;   Children's Research Institute
Recruiting - verified April 2012
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
Conditions:   Untreated Childhood Medulloblastoma;   Untreated Childhood Pineoblastoma;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions:   Drug: carboplatin;   Drug: cyclophosphamide;   Biological: filgrastim;   Drug: cisplatin;   Drug: isotretinoin;   Drug: vincristine sulfate;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
Conditions:   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Pineal Parenchymal Tumor
Interventions:   Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: carboplatin;   Drug: etoposide;   Drug: ifosfamide
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013
Childhood Cancer Survivor Study
Condition:   Cancer
Intervention:  
Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   National Cancer Institute (NCI);   Fred Hutchinson Cancer Research Center;   Nationwide Children's Hospital;   M.D. Anderson Cancer Center;   University of Southern California;   Children's Hospital Medical Center, Cincinnati
Recruiting - verified April 2013
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
Conditions:   Bacterial Infection;   Malignant Neoplasm;   Methicillin-resistant Staphylococcus Aureus Infection;   Nonmalignant Neoplasm;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions:   Drug: chlorhexidine gluconate;   Procedure: wound care management;   Other: questionnaire administration;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified November 2014
Clinical and Laboratory Study of Methylmalonic Acidemia
Conditions:   Amino Acid Metabolism;   Inborn Errors
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Human Genome Research Institute (NHGRI)
Recruiting - verified June 2013
Clinical Evaluator Outcomes Reliability Study
Condition:   Dystrophinopathies
Intervention:  
Sponsors:   Cooperative International Neuromuscular Research Group;   The Foundation to Eradicate Duchenne
Recruiting - verified May 2014
Clinical Outcome Study for Dysferlinopathy
Conditions:   Dysferlinopathy;   LGMD2B;   Miyoshi Myopathy
Intervention:  
Sponsors:   Newcastle-upon-Tyne Hospitals NHS Trust;   Newcastle-upon-Tyne Hospitals NHS Trust;   Jain Foundation (Grant sponsor)
Recruiting - verified October 2012
Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)
Conditions:   Craniosynostosis;   Muenke Syndrome
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Human Genome Research Institute (NHGRI)
Recruiting - verified July 2013
Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies
Conditions:   Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy;   Limb Girdle Muscular Dystrophy
Intervention:   Drug: Coenzyme Q10 and Lisinopril
Sponsors:   Cooperative International Neuromuscular Research Group;   Cooperative International Neuromuscular Research Group;   Department of Defense
Recruiting - verified September 2013
Cockroach Nasal Allergen Challenge Pilot
Conditions:   Asthma;   Cockroach Hypersensitivity
Intervention:   Biological: Glycerinated German Cockroach Allergenic Extract
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Inner-City Asthma Consortium
Recruiting - verified March 2016
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Conditions:   Epilepsy, Partial;   Epilepsy, Localization Related;   Adverse Effects
Interventions:   Drug: Oxcarbazepine;   Drug: levetiracetam;   Drug: lamotrigine
Sponsors:   Emory University;   Emory University;   Patient Centered Outcomes Research Institute
Not yet recruiting - verified June 2013
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
Condition:   Sarcoma
Interventions:   Other: biologic sample preservation procedure;   Other: medical chart review
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified November 2012
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Conditions:   Leukemia;   Neoplasm of Uncertain Malignant Potential;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Other: cytology specimen collection procedure
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified November 2012
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma
Condition:   Sarcoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified November 2012
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Conditions:   Leukemia;   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified November 2012
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Conditions:   Lymphoma;   Lymphoproliferative Disorder
Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified November 2012
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Conditions:   Adult Rhabdomyosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Chordoma;   Desmoid Tumor;   Metastatic Childhood Soft Tissue Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Previously Untreated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Stage I Adult Soft Tissue Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions:   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Conditions:   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Rhabdoid Tumor of the Kidney;   Stage I Wilms Tumor;   Stage II Wilms Tumor;   Stage III Wilms Tumor;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
Interventions:   Drug: doxorubicin hydrochloride;   Procedure: therapeutic conventional surgery;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: carboplatin;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Conditions:   Untreated Childhood Medulloblastoma;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions:   Drug: etoposide;   Drug: cyclophosphamide;   Drug: cisplatin;   Biological: filgrastim;   Drug: carboplatin;   Drug: thiotepa;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Conditions:   Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Childhood Supratentorial Primitive Neuroectodermal Tumor;   Ewing Sarcoma of Bone;   Extraosseous Ewing Sarcoma;   Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Peripheral Primitive Neuroectodermal Tumor of the Kidney;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions:   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: ifosfamide;   Drug: etoposide;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Cognitive/Functional Effects;   Neurotoxicity;   Pain;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Therapy-related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions:   Drug: clofarabine;   Drug: doxorubicin hydrochloride;   Drug: hydrocortisone sodium succinate;   Radiation: selective external radiation therapy;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: prednisone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: cyclophosphamide;   Drug: mercaptopurine;   Drug: leucovorin calcium;   Drug: thioguanine;   Drug: etoposide
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Conditions:   B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified August 2016
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer
Conditions:   Childhood Hepatoblastoma;   Stage I Childhood Liver Cancer;   Stage II Childhood Liver Cancer;   Stage III Childhood Liver Cancer;   Stage IV Childhood Liver Cancer
Interventions:   Procedure: therapeutic conventional surgery;   Drug: cisplatin;   Drug: fluorouracil;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: irinotecan hydrochloride;   Procedure: liver transplantation;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Conditions:   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions:   Drug: doxorubicin hydrochloride;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: prednisone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: mercaptopurine;   Drug: nelarabine;   Drug: asparaginase;   Drug: dexamethasone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified October 2013
Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma
Condition:   Untreated Childhood Medulloblastoma
Interventions:   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Etoposide;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Other: Cognitive Assessment
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified December 2014
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Conditions:   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions:   Drug: bortezomib;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: daunorubicin hydrochloride;   Drug: pegaspargase;   Drug: methotrexate;   Drug: cyclophosphamide;   Drug: mercaptopurine;   Drug: doxorubicin hydrochloride;   Drug: thioguanine;   Drug: hydrocortisone sodium succinate;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: etoposide;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified October 2014
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Conditions:   Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm to the Bone;   Metastatic Malignant Neoplasm to the Bone Marrow;   Metastatic Malignant Neoplasm to the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions:   Drug: Vincristine Sulfate;   Drug: Doxorubicin Hydrochloride;   Drug: Cyclophosphamide;   Drug: Ifosfamide;   Drug: Etoposide;   Biological: Ganitumab;   Procedure: Therapeutic Surgical Procedure;   Radiation: Stereotactic Radiosurgery;   Radiation: External Beam Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified December 2014
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions:   Acute Undifferentiated Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions:   Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: lestaurtinib;   Drug: cyclophosphamide;   Drug: pegaspargase;   Drug: prednisone;   Drug: methylprednisolone;   Drug: dexamethasone;   Drug: cytarabine;   Drug: methotrexate;   Biological: filgrastim;   Drug: leucovorin calcium;   Drug: etoposide;   Drug: mercaptopurine;   Drug: vincristine sulfate;   Drug: hydrocortisone sodium succinate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified July 2013
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma
Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organisation for Research and Treatment of Cancer - EORTC;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified December 2011
Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia
Conditions:   B-cell Childhood Acute Lymphoblastic Leukemia;   Childhood Diffuse Large Cell Lymphoma;   L3 Childhood Acute Lymphoblastic Leukemia;   Stage III Childhood Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions:   Biological: rituximab;   Drug: prednisone;   Drug: etoposide;   Drug: doxorubicin hydrochloride;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: cyclophosphamide;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: leucovorin calcium;   Drug: therapeutic hydrocortisone
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified September 2014
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
Condition:   Extraocular Retinoblastoma
Interventions:   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Biological: filgrastim;   Drug: carboplatin;   Drug: vincristine sulfate;   Drug: thiotepa;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
Conditions:   Brain Tumor;   Central Nervous System Tumor
Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: lomustine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013
Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
Conditions:   Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE);   Juvenile Dermatomyositis (JDM);   Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)
Intervention:   Drug: Baricitinib
Sponsor:   Eli Lilly and Company
Available - verified March 2016
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies
Conditions:   Sarcoma;   Endocrine Tumors;   Neuroblastoma;   Retinoblastoma;   Renal Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2012
Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy
Conditions:   Childhood Brain Tumor;   Cognitive/Functional Effects;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity
Interventions:   Other: computer-assisted cognitive training;   Other: questionnaire administration;   Procedure: cognitive assessment;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified August 2015
Continued Anticonvulsants After Resolution of Neonatal Seizures: a Patient-centered Comparative Effectiveness Study
Condition:   Neonatal Seizures
Interventions:   Other: Surveys;   Other: EEG
Sponsors:   University of Michigan;   University of California, San Francisco;   Children's Hospital Boston;   Children's Hospital of Philadelphia;   Children's Research Institute;   Massachusetts General Hospital;   Patient-Centered Outcomes Research Institute;   Stanford University
Not yet recruiting - verified May 2016
Corticosteroids for Children With Febrile Urinary Tract Infections
Conditions:   Acute Urinary Tract Infection;   Urinary Tract Infection
Interventions:   Drug: Placebo;   Drug: Dexamethasone
Sponsors:   University of Pittsburgh;   University of Pittsburgh;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Conditions:   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: crizotinib;   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: questionnaire administration
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2017
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Conditions:   Brain and Central Nervous System Tumors;   Lymphoma;   Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: crizotinib;   Other: pharmacogenomic studies;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified October 2012
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
Condition:   Cancer
Interventions:   Drug: cyproheptadine hydrochloride;   Other: placebo
Sponsors:   University of South Florida;   University of South Florida;   National Cancer Institute (NCI)
Recruiting - verified August 2013
Cytotoxic T Cells to Prevent Virus Infections
Conditions:   CMV;   EBV;   Adenovirus Infections
Intervention:   Drug: Cytotoxic T lymphocytes (CTLs).
Sponsors:   Children's Research Institute;   Children's Research Institute
Not yet recruiting - verified August 2013
Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma
Conditions:   Hodgkin Disease;   Non Hodgkin Lymphoma;   Lymphoepithelioma;   Severe Chronic Active EBV Infection Syndrome (SCAEBV);   Leiomyosarcoma
Interventions:   Drug: LMP1/2 CTLs (Group A);   Drug: LMP1/2 CTLs (Group B)
Sponsors:   Children's Research Institute;   Catherine Bollard
Not yet recruiting - verified October 2013
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Condition:   Hepatic Veno-Occlusive Disease
Interventions:   Drug: Defibrotide;   Drug: Defibrotide
Sponsors:   Gentium SpA;   Gentium SpA
Recruiting - verified October 2013
Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy
Condition:   Duchenne Muscular Dystrophy
Intervention:   Drug: Deflazacort
Sponsors:   Marathon Pharmaceuticals, LLC;   Parexel;   Dohmen Life Science Services
Available - verified October 2015
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Conditions:   Childhood Osteosarcoma;   Metastatic Osteosarcoma;   Recurrent Osteosarcoma
Interventions:   Biological: Denosumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified January 2016
Dental Malocclusion and Craniofacial Development in OI
Condition:   Osteogenesis Imperfecta
Intervention:  
Sponsors:   Baylor College of Medicine;   Shriners Hospitals for Children;   Hospital for Special Surgery, New York;   University of Nebraska;   Hugo W. Moser Research Institute at Kennedy Krieger, Inc.;   Children's Research Institute;   University of California, Los Angeles;   Oregon Health and Science University
Recruiting - verified October 2016
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)
Conditions:   Neurofibromatosis 1;   Plexiform Neurofibromas
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified August 2015
Development of a City-Wide Cohort of HIV-Infected Persons in Care in the District of Columbia: The DC Cohort
Conditions:   HIV;   AIDS
Intervention:  
Sponsors:   George Washington University;   George Washington University;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2013
Dexmedetomidine to Treat Bariatric Surgery-associated Pain
Condition:   Obesity
Interventions:   Drug: Fentanyl;   Drug: Morphine;   Drug: Dexmedetomidine
Sponsor:   Children's Research Institute
Recruiting - verified August 2016
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
Conditions:   Metastatic Malignant Neoplasm in the Lung;   Metastatic Osteosarcoma;   Recurrent Osteosarcoma
Interventions:   Biological: Dinutuximab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Sargramostim
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified April 2016
Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?
Conditions:   Cervical Cancer;   Hpv;   Warts
Intervention:   Biological: Quadrivalent HPV for types 6, 11, 16 and 18
Sponsors:   Medstar Research Institute;   Medstar Research Institute;   Merck
Recruiting - verified February 2011
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
Condition:   Leukemia
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2013
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Conditions:   Rhabdomyosarcoma and Other Soft Tissue Sarcomas;   Ewing's Sarcoma Family of Tumors;   Osteosarcoma;   Neuroblastoma;   Brain Tumors
Interventions:   Drug: sorafenib;   Drug: irinotecan
Sponsors:   Children's Research Institute;   Children's Research Institute
Recruiting - verified January 2012
Down Syndrome Metabolic Health Study
Conditions:   Down Syndrome;   Trisomy 21
Intervention:  
Sponsors:   Children's Hospital of Philadelphia;   National Institutes of Health (NIH);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2015
Effect of Carnitine Deficiency on Myocardial Function in Children Receiving Continuous Renal Replacement Therapy
Condition:   Acute Renal Failure
Intervention:   Drug: Carnitine
Sponsors:   Children's Research Institute;   Children's Research Institute
Not yet recruiting - verified September 2013
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects
Condition:   Post Operative Pain
Intervention:   Drug: oxymorphone HCl
Sponsors:   Endo Pharmaceuticals;   Endo Pharmaceuticals
Recruiting - verified May 2013
Efficacy of Amicar for Children Having Craniofacial Surgery
Condition:   Craniosynostosis
Intervention:   Drug: epsilon aminocaproic acid
Sponsor:   Children's Research Institute
Not yet recruiting - verified August 2014
Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media
Condition:   Acute Otitis Media
Interventions:   Procedure: Tympanostomy tube placement;   Procedure: Nonsurgical management
Sponsors:   University of Pittsburgh;   George Washington University;   National Institute on Deafness and Other Communication Disorders (NIDCD)
Not yet recruiting - verified October 2015
Efficacy Study Of Tofacitinib In Pediatric JIA Population
Condition:   Juvenile Idiopathic Arthritis
Interventions:   Drug: CP-690,550 (tofacitinib);   Other: placebo
Sponsor:   Pfizer
Recruiting - verified June 2016
Efficacy, Safety, and PK of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
Condition:   Central Precocious Puberty
Intervention:   Drug: Triptorelin 22.5 mg
Sponsors:   Debiopharm International SA;   Debiopharm International SA
Recruiting - verified May 2013
Eisenmenger Quality Enhancement Research Initiative
Condition:   Eisenmenger
Intervention:   Other: Management
Sponsors:   Actelion;   Actelion
Recruiting - verified May 2013
Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
Conditions:   Pleuropulmonary Blastoma;   Cystic Nephroma;   Sertoli-Leydig Tumor;   Medulloepithelioma;   Embryonal Rhabdomyosarcoma of Uterine Cervix
Intervention:  
Sponsor:   Children's Research Institute
Recruiting - verified January 2014
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Conditions:   Childhood Brain Stem Neoplasm;   Childhood Lymphoma;   Childhood Solid Neoplasm;   Pineal Region Neoplasm;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Visual Pathway Glioma;   Refractory Central Nervous System Neoplasm
Interventions:   Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified January 2017
Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis
Condition:   Pediatric Multiple Sclerosis
Intervention:  
Sponsors:   University of California, San Francisco;   Stony Brook University;   Massachusetts General Hospital;   State University of New York at Buffalo;   University of Alabama at Birmingham;   Mayo Clinic;   Children's Hospital Philadelphia;   Children's Hospital Boston;   Texas Children's Hospital;   Loma Linda University;   Children's Hospital Colorado;   University of Texas;   Ann & Robert H Lurie Children's Hospital of Chicago;   Washington University School of Medicine;   Children's National Med Center;   Primary Children's Medical Center
Recruiting - verified April 2014
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
Condition:   Recurrent Osteosarcoma
Interventions:   Drug: eribulin mesylate;   Other: pharmacological study
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified September 2014
Established Status Epilepticus Treatment Trial
Condition:   Benzodiazipine Refractory Status Epilepticus
Interventions:   Drug: Fosphenytoin;   Drug: Levetiracetam;   Drug: Valproic acid
Sponsors:   University of Virginia;   University of Michigan;   Medical University of South Carolina;   Children's Research Institute;   University of Minnesota - Clinical and Translational Science Institute;   National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting - verified August 2015
Evaluating the Response to Three Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 28 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
Condition:   HIV Infections
Interventions:   Drug: Lamivudine/zidovudine;   Drug: Lopinavir/ritonavir;   Drug: Efavirenz;   Drug: Raltegravir
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified September 2013
Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN #0601) (The SCURT Study)
Condition:   Sickle Cell Disease
Intervention:   Biological: Hematopoietic Stem Cell Transplantation
Sponsors:   Medical College of Wisconsin;   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI);   National Marrow Donor Program;   Sickle Cell Disease Clinical Research Network
Recruiting - verified May 2013
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
Condition:   HIV Infections
Intervention:   Drug: Etravirine (ETR)
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2013
Evaluation of the Duration of Therapy for Thrombosis in Children
Condition:   Venous Thrombosis
Interventions:   Other: Shortened duration (6 weeks) of anticoagulant therapy;   Other: Conventional duration (3 months) of anticoagulant therapy;   Other: No Intervention;   Other: No Intervention;   Drug: Dalteparin
Sponsors:   University of Colorado, Denver;   University of Colorado, Denver;   National Heart, Lung, and Blood Institute (NHLBI);   Hemophilia and Thrombosis Research Society;   Eisai Inc.
Recruiting - verified January 2013
Evaluation of the PK and PD of Ganciclovir in Premature Infants Receiving Treatment for CMV Infection
Condition:   Cytomegalovirus Infections
Intervention:  
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham
Not yet recruiting - verified January 2013
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Condition:   CD33 Positive Acute Myelogenous Leukemia
Intervention:   Biological: Antibody Drug Conjugate Chemotherapeutic
Sponsor:   Pfizer
Available - verified March 2016
Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Condition:   Adenovirus
Intervention:   Drug: Brincidofovir
Sponsor:   Chimerix
Available - verified December 2016
Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
Condition:   Radiation Therapy
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2012
Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002
Condition:   X-linked Hypohidrotic Ectodermal Dysplasia
Intervention:   Drug: EDI200
Sponsor:   Edimer Pharmaceuticals
Recruiting - verified March 2014
Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
Conditions:   Malignant Glioma;   Ependymoma
Intervention:   Device: Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)
Sponsors:   Pediatric Brain Tumor Consortium;   National Cancer Institute (NCI)
Recruiting - verified January 2017
Finding the Optimum Regimen for Duchenne Muscular Dystrophy
Condition:   Duchenne Muscular Dystrophy
Interventions:   Drug: Prednisone;   Drug: Prednisone;   Drug: Deflazacort
Sponsors:   University of Rochester;   Newcastle University;   University Medical Center Freiburg;   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified November 2014
Fludarabine-based Conditioning for Severe Aplastic Anemia
Condition:   Anemia, Aplastic
Interventions:   Drug: Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Cyclophosphamide
Sponsors:   Medical College of Wisconsin;   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
Recruiting - verified June 2013
Fontan Udenafil Exercise Longitudinal Assessment Trial
Condition:   Fontan Palliation
Interventions:   Drug: Udenafil;   Drug: Placebo
Sponsors:   Mezzion Pharma Co. Ltd;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified April 2016
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
Condition:   Recurrent Osteosarcoma
Interventions:   Drug: Glembatumumab Vedotin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified April 2016
GM-CSF for Immunomodulation Following Trauma (GIFT) Study
Condition:   Critical Injury (Trauma) in Children
Intervention:   Drug: GM-CSF
Sponsors:   Mark Hall;   National Institute of General Medical Sciences (NIGMS);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2016
GPS (Giving Parents Support): Parent Navigation After NICU Discharge
Conditions:   Premature Birth of Newborn;   Family;   Immature Newborn;   Newborn Morbidity;   Infant Newborn Disease
Interventions:   Behavioral: Parent Navigator;   Behavioral: Care Notebook
Sponsors:   Children's Research Institute;   Patient-Centered Outcomes Research Institute
Recruiting - verified December 2015
Haploidentical Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease and Thalassemia Using CD34+ Positive Selected Grafts
Conditions:   Sickle Cell-thalassemia Disease;   Thalassemia
Intervention:   Drug: peripheral blood stem cell graft that are CD34+ selected
Sponsors:   Children's Research Institute;   Catherine Bollard
Not yet recruiting - verified June 2014
Healthy Eating, Physical Activity, and Glycemic Control in Young Children With T1D
Condition:   Diabetes Mellitus, Type 1
Intervention:   Behavioral: Type One Training (TOT)
Sponsors:   Randi Streisand;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified January 2015
High-dose Erythropoietin for Asphyxia and Encephalopathy
Conditions:   Neonatal Encephalopathy;   Birth Asphyxia
Interventions:   Drug: Normal saline placebo;   Drug: erythropoietin
Sponsors:   University of California, San Francisco;   University of Washington;   Mednax Center for Research, Education and Quality;   University of Utah;   Children's Research Institute;   University of Minnesota - Clinical and Translational Science Institute;   University of Texas;   Washington University School of Medicine;   Indiana University;   Stanford University;   University of Pittsburgh;   University of California, Davis;   Northwestern;   Children's Hospital Los Angeles;   Nationwide Children's Hospital;   Johns Hopkins University;   Boston University;   University of New Mexico;   University of Chicago;   University of North Carolina
Not yet recruiting - verified June 2016
Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders
Condition:   Urea Cycle Disorders
Intervention:   Biological: HHLivC
Sponsors:   Cytonet GmbH & Co. KG;   Cytonet GmbH & Co. KG
Recruiting - verified July 2013
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
Condition:   Hemophagocytic Lymphohistiocytosis
Interventions:   Drug: ATG, rabbit;   Drug: Etoposide;   Drug: Methotrexate;   Drug: hydrocortisone;   Drug: Dexamethasone
Sponsor:   Children's Hospital Medical Center, Cincinnati
Recruiting - verified August 2015
Hypothermia's Impact on Pharmacology
Conditions:   Cardiac Arrest;   Hypothermia
Intervention:  
Sponsors:   Children's Hospital of Philadelphia;   Children's Hospital of Philadelphia
Recruiting - verified February 2013
iCAT for Recurrent/Refractory/HR Solid Tumors
Conditions:   Pediatric Solid Tumor;   Sarcoma;   Neuroblastoma;   Wilms Tumor
Intervention:  
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified May 2013
Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture
Condition:   Herpes Simplex Virus
Intervention:   Device: Genexpert assay
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham
Not yet recruiting - verified June 2013
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Conditions:   Recurrent Childhood Anaplastic Astrocytoma;   Recurrent Childhood Anaplastic Ependymoma;   Recurrent Childhood Diffuse Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Giant Cell Glioblastoma;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Gliosarcoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor (PNET);   Recurrent Childhood Brain Stem Glioma
Interventions:   Drug: imetelstat sodium;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Pediatric Brain Tumor Consortium;   National Cancer Institute (NCI)
Recruiting - verified February 2014
Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis
Condition:   Gastroenteritis
Interventions:   Drug: LGG;   Drug: micro-crystalline cellulose
Sponsors:   Washington University School of Medicine;   Columbia University;   Northwestern University;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Children's Research Institute;   University of Utah;   Wayne State University;   Children's Hospital Medical Center, Cincinnati;   University of Michigan;   Brown University;   University of California, Davis
Recruiting - verified December 2014
Impact of Emergency Department Probiotic Treatment of Pediatric Gastroenteritis
Conditions:   Gastroenteritis;   Child
Interventions:   Dietary Supplement: Lacidofil;   Dietary Supplement: placebo
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Not yet recruiting - verified May 2011
Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB
Condition:   Lower Urinary Tract Symptoms
Intervention:   Drug: Lactobacillus rhamnosus GG
Sponsors:   Medstar Research Institute;   Patient-Centered Outcomes Research Institute;   Georgetown University;   Children's Research Institute
Recruiting - verified April 2016
Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB
Condition:   Lower Urinary Tract Symptoms
Intervention:   Drug: Lactobacillus
Sponsors:   Medstar Research Institute;   Patient-Centered Outcomes Research Institute;   Children's Research Institute;   Georgetown University
Recruiting - verified April 2016
Improvement of STI Detection in Adolescent Emergency Department Patients
Condition:   Sexually Transmitted Infections
Intervention:   Behavioral: Sexual health screen (SHS)
Sponsor:   Children's Research Institute
Recruiting - verified July 2015
Improving Asthma Outcomes Through Stress Management
Condition:   Asthma
Interventions:   Behavioral: Parental stress management;   Other: Usual Care
Sponsors:   Stephen J. Teach, MD, MPH;   Patient Centered Outcome Research Institute
Not yet recruiting - verified February 2015
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: ruxolitinib phosphate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified October 2012
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Conditions:   Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions:   Drug: doxorubicin hydrochloride;   Drug: irinotecan hydrochloride;   Other: pharmacological study;   Other: questionnaire administration;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: cisplatin;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Radiation: iobenguane I 131;   Drug: busulfan;   Drug: melphalan;   Drug: isotretinoin
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2014
Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI
Condition:   Ornithine Transcarbamylase Deficiency
Interventions:   Behavioral: MRI scanning;   Behavioral: Cognitive testing
Sponsors:   Children's Research Institute;   Children's Research Institute
Recruiting - verified March 2012
Investigation of Six Weeks of Oral Valganciclovir Therapy in Infants and Children With Congenital Cytomegalovirus Infection and Hearing Loss
Conditions:   Congenital Cytomegalovirus;   Hearing Loss
Interventions:   Drug: Valganciclovir;   Drug: Placebo
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham
Not yet recruiting - verified March 2013
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Condition:   Recurrent Neuroblastoma
Interventions:   Drug: irinotecan hydrochloride;   Drug: temozolomide;   Drug: temsirolimus;   Biological: monoclonal antibody Ch14.18;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified September 2013
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma
Conditions:   Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions:   Drug: isotretinoin;   Biological: sargramostim;   Biological: monoclonal antibody Ch14.18;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified August 2013
L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects
Condition:   Acute Lung Injury
Interventions:   Drug: L-citrulline;   Other: Placebo
Sponsor:   Asklepion Pharmaceuticals, LLC
Recruiting - verified September 2016
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Bacterial Infection;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Disseminated Neuroblastoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   High Risk Metastatic Gestational Trophoblastic Tumor;   Juvenile Myelomonocytic Leukemia;   Musculoskeletal Complications;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Neutropenia;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Plasma Cell Neoplasm;   Previously Treated Childhood Rhabdomyosarcoma;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Prolymphocytic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Neuroblastoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage II Ovarian Epithelial Cancer;   Stage II Ovarian Germ Cell Tumor;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Ovarian Epithelial Cancer;   Stage III Ovarian Germ Cell Tumor;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Small Lymphocytic Lymphoma;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions:   Drug: levofloxacin;   Procedure: standard follow-up care
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified July 2013
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Acute Undifferentiated Leukemia;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Intraocular Lymphoma;   Isolated Plasmacytoma of Bone;   Juvenile Myelomonocytic Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Mast Cell Leukemia;   Meningeal Chronic Myelogenous Leukemia;   Monoclonal Gammopathy of Undetermined Significance;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Primary Myelofibrosis;   Primary Systemic Amyloidosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions:   Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013
Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia
Conditions:   Propionic Acidemia (PA);   Methylmalonic Acidemia (MMA)
Intervention:   Drug: N-carbamylglutamate
Sponsors:   Children's Research Institute;   Children's Research Institute;   Children's Hospital Boston;   University Hospitals of Cleveland;   Children's Hospital of Colorado;   University of California, Los Angeles;   Children's Hospital of Philadelphia;   Seattle Children's Hospital
Recruiting - verified July 2013
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Condition:   Fibrosing Colonopathy in Patients With Cystic Fibrosis
Interventions:   Biological: CREON;   Biological: ZENPEP;   Biological: ULTRESA;   Biological: PANCREAZE;   Biological: other non-sponsor pancreatic enzyme replacement therapy;   Other: No pancreatic enzyme replacement therapy
Sponsors:   AbbVie (prior sponsor, Abbott);   Cystic Fibrosis Foundation Therapeutics;   Janssen Research & Development, LLC;   Forest Laboratories
Recruiting - verified April 2017
Longitudinal Pediatric Palliative Care: Quality of Life & Spiritual Struggle
Condition:   HIV
Interventions:   Behavioral: FAmily CEntered (FACE) ACP;   Behavioral: Healthy Living Control
Sponsors:   Children's Research Institute;   Children's Research Institute;   St. Jude Children's Research Hospital;   Johns Hopkins University;   University of Miami
Recruiting - verified October 2012
Longitudinal Study of the Natural History of Duchenne Muscular Dystrophy (DMD)
Condition:   Duchenne Muscular Dystrophy
Intervention:  
Sponsors:   Cooperative International Neuromuscular Research Group;   Cooperative International Neuromuscular Research Group;   U.S. Department of Education;   National Institutes of Health (NIH);   Department of Defense
Recruiting - verified July 2013
Longitudinal Study of Urea Cycle Disorders
Conditions:   Brain Diseases, Metabolic, Inborn;   Amino Acid Metabolism, Inborn Errors;   Urea Cycle Disorders
Intervention:  
Sponsors:   Children's Research Institute;   Children's Research Institute;   National Center for Research Resources (NCRR);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Rare Diseases Clinical Research Network
Recruiting - verified February 2013
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Conditions:   Pleuropulmonary Blastoma;   Recurrent Malignant Peripheral Nerve Sheath Tumor;   Recurrent Neuroblastoma;   Recurrent Rhabdomyosarcoma;   Recurrent Synovial Sarcoma;   Wilms Tumor
Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Lorvotuzumab Mertansine;   Other: Pharmacological Study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified December 2015
Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia
Conditions:   Idiopathic Scoliosis;   Spondylolisthesis
Interventions:   Drug: Ketamine;   Drug: Normal Saline
Sponsors:   Children's Research Institute;   Children's Research Institute
Recruiting - verified March 2012
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Conditions:   Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
Intervention:   Drug: lenalidomide
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified June 2013
Lurasidone Pediatric Bipolar Study
Condition:   Bipolar I Depression
Interventions:   Drug: Lurasidone;   Drug: Placebo
Sponsor:   Sunovion
Recruiting - verified January 2015
Magnesium in Crisis
Condition:   Sickle Cell Disease
Interventions:   Drug: Intravenous Magnesium Sulfate;   Drug: Normal Saline Placebo
Sponsors:   Medical College of Wisconsin;   Medical College of Wisconsin;   Pediatric Emergency Care Applied Research Network
Recruiting - verified July 2013
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
Conditions:   Childhood Infratentorial Ependymoma;   Childhood Supratentorial Ependymoma;   Newly Diagnosed Childhood Ependymoma
Interventions:   Drug: liposomal vincristine sulfate;   Other: clinical observation;   Radiation: 3-dimensional conformal radiation therapy;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: cisplatin;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013
Mechanisms of Sleep Disturbance in Children With Generalized Anxiety Disorder (GAD)
Conditions:   Generalized Anxiety Disorder;   Sleep Disturbances
Intervention:  
Sponsors:   Children's Research Institute;   Children's Research Institute
Recruiting - verified May 2011
Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy
Conditions:   Asthma;   Asthma Exacerbations
Intervention:  
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Inner City Asthma Consortium (ICAC)
Not yet recruiting - verified July 2015
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
Condition:   Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
Intervention:   Drug: PD-0325901
Sponsor:   University of Alabama at Birmingham
Recruiting - verified March 2014
Metabolism and Toxicity of Acetaminophen
Condition:   Pain
Intervention:   Drug: Acetaminophen
Sponsors:   Children's Research Institute;   Children's Research Institute
Recruiting - verified April 2012
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor
Conditions:   Brain and Central Nervous System Tumors;   Cognitive/Functional Effects;   Fatigue;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment
Interventions:   Drug: modafinil;   Other: placebo
Sponsors:   University of South Florida;   University of South Florida;   National Cancer Institute (NCI)
Recruiting - verified September 2011
Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
Conditions:   Diffuse Intrinsic Pontine Glioma;   Brainstem Glioma
Intervention:  
Sponsors:   Children's Research Institute;   Children's Research Institute
Recruiting - verified April 2012
Molecular Profiling for Individualized Treatment Plan for DIPG
Condition:   Diffuse Intrinsic Pontine Glioma (DIPG)
Interventions:   Other: Specialized tumor board recommendation;   Radiation: Standard radiation therapy
Sponsors:   University of California, San Francisco;   Translational Genomics Research Institute, Phoenix, Arizona.
Recruiting - verified July 2016
Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children
Condition:   Leukemia
Interventions:   Drug: Bortezomib;   Drug: Pravastatin
Sponsors:   Reuven Schore;   Millennium Pharmaceuticals, Inc.;   Hyundai Hope on Wheels Foundation
Recruiting - verified June 2015
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions:   Biological: anti-endosialin/TEM1 monoclonal antibody MORAb-004;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsors:   Morphotek;   Morphotek;   National Cancer Institute (NCI);   The Children's Oncology Group (COG)
Not yet recruiting - verified October 2013
Motivational Enhancement System for Adherence (MESA) for Youth Starting ART
Condition:   Medication Adherence
Intervention:   Behavioral: MESA
Sponsors:   Wayne State University;   National Institute of Mental Health (NIMH)
Recruiting - verified May 2016
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia
Condition:   Acute Myeloid Leukemia
Intervention:  
Sponsors:   Center for International Blood and Marrow Transplant Research;   Center for International Blood and Marrow Transplant Research;   Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT);   Pediatric Blood and Marrow Transplant Consortium;   St. Baldrick's Foundation;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified September 2013
MRI Markers of Outcome After Severe Pediatric TBI
Condition:   Brain Injuries
Intervention:   Other: MRI Scans
Sponsors:   University of Wisconsin, Madison;   National Institutes of Health (NIH);   National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting - verified February 2016
Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)
Conditions:   Mucopolysaccharidosis;   Mucopolysaccharidosis I;   Mucopolysaccharidosis II;   Mucopolysaccharidosis VI
Intervention:  
Sponsor:   Shire
Recruiting - verified July 2014
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Condition:   Relapsed/Refractory Hematopoietic Malignancies
Intervention:   Biological: Tumor associated antigen lymphocytes (TAA-CTL)
Sponsors:   Children's Research Institute;   Catherine Bollard
Not yet recruiting - verified July 2014
Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease
Condition:   Legg Calve Perthes Disease
Interventions:   Procedure: osteotomy;   Procedure: multiple epiphyseal drilling
Sponsor:   Texas Scottish Rite Hospital for Children
Recruiting - verified January 2014
Multivirus-specific Cytotoxic T Lymphocytes (mCTL)
Condition:   Refractory Viral Infections
Intervention:   Biological: mCTLs
Sponsors:   Catherine Bollard;   Children's Research Institute
Recruiting - verified July 2015
Myocardial Perfusion and Scarring in Congenital Heart Disease
Condition:   Congenital Heart Disease
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI);   Children's Research Institute;   Suburban Hospital
Recruiting - verified May 2013
N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia
Condition:   Inborn Errors of Metabolism
Intervention:   Drug: N-carbamylglutamate
Sponsors:   Children's Research Institute;   Children's Research Institute
Recruiting - verified March 2011
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Conditions:   Acute Lymphoblastic Leukemia/Lymphoma;   Myelodysplasia;   Acute Myelogenous Leukemia;   Juvenile Myelomonocytic Leukemia;   Chronic Myelogenous Leukemia
Intervention:  
Sponsors:   Center for International Blood and Marrow Transplant Research;   Pediatric Blood and Marrow Transplant Consortium;   National Marrow Donor Program
Not yet recruiting - verified January 2015
Natural History and Outcomes in X-Linked Hypohidrotic Ectodermal Dysplasia
Condition:   X-Linked Hypohidrotic Ectodermal Dysplasia
Intervention:  
Sponsor:   Edimer Pharmaceuticals
Not yet recruiting - verified March 2014
Natural History of Sickle Cell Disease and Other Hemolytic Disorders
Conditions:   Hemoglobin SC Disease;   Hematologic Diseases;   Sickle Cell Anemia;   Hemolytic Anemia
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified October 2016
Natural History Study of SCID Disorders
Conditions:   SCID;   Leaky SCID;   Omenn Syndrome;   Reticular Dysgenesis;   ADA Deficiency;   XSCID
Intervention:  
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   Office of Rare Diseases (ORD)
Recruiting - verified June 2013
Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEAT O)
Conditions:   Hypoxic-ischemic Encephalopathy;   Neonatal Encephalopathy;   Birth Asphyxia
Interventions:   Drug: Erythropoietin;   Drug: Normal saline
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   Thrasher Research Fund;   Seattle Children's Hospital;   Arkansas Children's Hospital Research Institute;   Washington University School of Medicine;   Children's Research Institute
Not yet recruiting - verified July 2013
Neuroimaging and Neurocognitive Assessment and Response to Sapropterin Dihydrochloride Treatment in Phenylketonuria
Condition:   PKU
Interventions:   Dietary Supplement: diet;   Drug: sapropterin dihydrochloride
Sponsors:   Children's Research Institute;   Children's Research Institute;   Georgetown University
Recruiting - verified March 2012
Neuropsychological and Behavioral Testing in Young Patients With Cancer
Conditions:   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Other: questionnaire administration;   Procedure: cognitive assessment;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013
New Diagnostic and Therapeutic Approaches in Leukodystrophy
Conditions:   White Matter Diseases;   Leukodystrophy
Interventions:   Other: Whole Genome Sequencing (WGS);   Other: Standard Clinical Care and Diagnostic Approaches
Sponsors:   Children's Research Institute;   Illumina, Inc.
Recruiting - verified March 2016
New Needle for Two-Needle Hemodialysis
Condition:   End Stage Renal Disease
Interventions:   Procedure: Hemodialysis using the standard venous needle;   Procedure: Hemodialysis using a new venous needle, the "BME needle";   Procedure: Hemodialysis using a new venous needle, the "BME needle";   Procedure: Hemodialysis using the standard venous needle
Sponsors:   Biomedical Enterprises Inc;   Biomedical Enterprises Inc;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified August 2011
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Conditions:   Childhood Solid Neoplasm;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
Interventions:   Biological: Nivolumab;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified March 2015
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
Conditions:   Mitochondrial Disorders;   Mitochondrial Genetic Disorders;   Mitochondrial Diseases;   Disorder of Mitochondrial Respiratory Chain Complexes;   Deletion and Duplication of Mitochondrial DNA
Intervention:  
Sponsor:   Columbia University
Recruiting - verified November 2013
Objective Measurement of Pain Using the Algometer
Condition:   Healthy
Intervention:   Device: Pressure Algometer Testing
Sponsors:   Julia Finkel;   CoolCad Electronics, LLC; University of Maryland Engineering
Recruiting - verified December 2014
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Condition:   Rheumatic Joint Disease
Intervention:  
Sponsors:   Duke University;   Childhood Arthritis and Rheumatology Research Alliance
Recruiting - verified November 2015
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
Conditions:   Leukemia;   Leukemia,Pediatric;   Leukemia, Myleiod;   Leukemia, Mylegenous, Chronic;   Leukemia, Mylegenous, Accelerated;   BCR-ABL Positive;   Myeloproliferative Disorder;   Bone Marrow Disease;   Hematologic Diseases;   Neoplastic Processes;   Imatinib;   Dasatinib;   Enzyme Inhibitor;   Protein Kinase Inhibitor
Intervention:   Drug: nilotinib
Sponsors:   Novartis;   Novartis Pharmaceuticals;   Children's Oncology Group;   Innovative Therapies for Children with Cancer, European Consortium
Recruiting - verified April 2014
Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)
Condition:   Severe Aplastic Anemia
Interventions:   Drug: Antithymocyte Globulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI);   Procedure: UCB HSCT;   Procedure: Haplo HSCT;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Drug: G-CSF
Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program
Not yet recruiting - verified September 2016
Optimizing the Use of Morphine in Pre-Term Neonates
Condition:   Critically Ill Premature Neonates
Interventions:   Drug: Morphine;   Drug: Morphine
Sponsors:   Children's Research Institute;   Children's Research Institute;   University of Louisville;   State University of New York - Downstate Medical Center
Recruiting - verified April 2012
Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders
Condition:   Urea Cycle Disorders
Intervention:  
Sponsors:   Children's Research Institute;   Children's Research Institute;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Rare Diseases Clinical Research Network
Recruiting - verified April 2013
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
Conditions:   Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Choroid Plexus Tumor;   Recurrent Childhood Anaplastic Astrocytoma;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Giant Cell Glioblastoma;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Gliosarcoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions:   Drug: azurin-derived cell-penetrating peptide p28;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Pediatric Brain Tumor Consortium;   National Cancer Institute (NCI)
Recruiting - verified October 2013
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Conditions:   Childhood Choroid Plexus Tumor;   Childhood Ependymoblastoma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Medulloepithelioma;   Recurrent Childhood Anaplastic Astrocytoma;   Recurrent Childhood Anaplastic Oligoastrocytoma;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Giant Cell Glioblastoma;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Gliomatosis Cerebri;   Recurrent Childhood Gliosarcoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions:   Drug: palbociclib isethionate;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsors:   Pediatric Brain Tumor Consortium;   National Cancer Institute (NCI)
Not yet recruiting - verified September 2014
Palliative Care in People Living With HIV/AIDS: Integrating Into Standard of Care
Condition:   HIV
Interventions:   Behavioral: FAmily-CEntered Advance Care Planning;   Behavioral: Healthy Living Control
Sponsors:   Children's Research Institute;   Children's Research Institute;   Georgetown University;   George Washington University;   Department of Veterans Affairs
Not yet recruiting - verified January 2013
Panobinostat in Treating Younger Patients With Progressive Diffuse Intrinsic Pontine Glioma
Condition:   Diffuse Intrinsic Pontine Glioma
Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Panobinostat;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified May 2016
Parental Management of Young Children's Diabetes
Condition:   Diabetes Mellitus, Type 1
Interventions:   Behavioral: Parental Support;   Behavioral: Diabetes Education
Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Children's Research Institute;   Virginia Commonwealth University
Recruiting - verified February 2011
Patient Centered Comprehensive Medication Adherence Management System in Patients With Sickle Cell Disease
Condition:   Sickle Cell Disease
Intervention:   Behavioral: Mobile DOT
Sponsors:   Emory University;   Patient Centered Outcome Research Institute
Recruiting - verified February 2015
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Conditions:   Septic Shock;   Thrombocytopenia;   Multiple Organ Failure
Intervention:  
Sponsors:   Children's Healthcare of Atlanta;   Children's Healthcare of Atlanta
Recruiting - verified May 2009
Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995
Condition:   Granulomatous Disease, Chronic
Intervention:  
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Primary Immune Deficiency Treatment Consortium (PIDTC);   Rare Diseases Clinical Research Network (RDCRN);   Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Not yet recruiting - verified March 2014
Patients Treated for SCID (1968-2010)
Conditions:   SCID;   ADA-SCID;   XSCID;   Leaky SCID;   Omenn Syndrome;   Reticular Dysgenesis
Intervention:  
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   Office of Rare Diseases (ORD)
Recruiting - verified June 2013
Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990
Condition:   Wiskott-Aldrich Syndrome
Intervention:  
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Primary Immune Deficiency Treatment Consortium (PIDTC);   Rare Diseases Clinical Research Network (RDCRN)
Not yet recruiting - verified February 2014
PEACE: Pediatric Antifungal Comparative Effectiveness
Condition:   Pediatric Invasive Candidiasis
Intervention:   Drug: Observational antifungal therapy
Sponsors:   Duke University;   Children's Hospital of Philadelphia
Recruiting - verified September 2015
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
Condition:   Peanut Allergy
Interventions:   Biological: AR101 powder provided in capsules & sachets;   Biological: Placebo powder provided in capsules & sachets
Sponsor:   Aimmune Therapeutics, Inc.
Recruiting - verified June 2016
PECARN Emergency Care Registry
Condition:   Pediatric Emergency Care
Intervention:  
Sponsors:   Children's Hospital of Philadelphia;   Children's Hospital of Philadelphia;   Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified February 2013
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Condition:   Leukemia, Pediatric
Intervention:   Drug: Dasatinib
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Children's Oncology Group;   EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified October 2013
Pediatric Schizophrenia Efficacy and Safety Study
Condition:   Schizophrenia
Interventions:   Drug: Lurasidone 40 mg;   Drug: Lurasidone 80 mg;   Drug: Placebo 40 or 80 mg
Sponsor:   Sunovion
Recruiting - verified September 2014
Pediatric Vasculitis Initiative
Conditions:   Wegeners Granulomatosis;   Microscopic Polyangiitis;   Churg Strauss Syndrome;   Polyarteritis Nodosa;   Takayasu Arteritis;   Primary CNS Vasculitis;   Unclassified Vasculitis
Intervention:  
Sponsors:   University of British Columbia;   Canadian Institutes of Health Research (CIHR);   Simon Fraser University;   Child and Family Research Institute;   Alberta Children's Hospital;   University Hospital Muenster;   The Hospital for Sick Children;   University of Oxford
Recruiting - verified February 2014
Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery
Condition:   Childhood Craniopharyngioma
Interventions:   Biological: peginterferon alfa-2b;   Other: laboratory biomarker analysis
Sponsors:   Pediatric Brain Tumor Consortium;   Pediatric Brain Tumor Consortium;   National Cancer Institute (NCI)
Not yet recruiting - verified October 2013
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
Conditions:   Diffuse Intrinsic Pontine Glioma;   Malignant Glioma;   Recurrent Childhood Brain Neoplasm
Interventions:   Procedure: Diffusion Tensor Imaging;   Procedure: Diffusion Weighted Imaging;   Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;   Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging;   Other: Laboratory Biomarker Analysis;   Procedure: Magnetic Resonance Spectroscopic Imaging;   Biological: Pembrolizumab;   Procedure: Perfusion Magnetic Resonance Imaging
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified May 2015
Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults
Condition:   HIV Infections
Interventions:   Drug: Raltegravir (RAL);   Drug: Atazanavir (ATV);   Drug: Ritonavir (RTV);   Drug: Tenofovir (TDF);   Drug: Etravirine (ETV);   Drug: Darunavir (DRV);   Drug: Maraviroc (MVC);   Drug: Lopinavir/ritonavir (LPV/r)
Sponsors:   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2013
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Condition:   HIV Infections
Interventions:   Drug: Current ARV medications;   Drug: Current TB medications;   Drug: Current hormonal contraceptive medications
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2013
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Conditions:   Infection;   Hypertension;   Anesthesia;   Pain;   Reflux
Intervention:   Drug: Ampicillin
Sponsors:   Duke University;   Daniel Benjamin;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   The EMMES Corporation
Recruiting - verified May 2013
Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs
Condition:   Central Nervous System
Intervention:   Drug: perampanel
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified October 2013
Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents
Conditions:   Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
Intervention:   Drug: E/C/F/TAF
Sponsor:   Gilead Sciences
Recruiting - verified December 2013
Pharmacokinetics, Safety, and Efficacy of Cobicistat-boosted Atazanavir or Cobicistat-boosted Darunavir in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects
Conditions:   Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
Interventions:   Drug: ATV;   Drug: DRV;   Drug: Cobicistat;   Drug: BR
Sponsor:   Gilead Sciences
Recruiting - verified March 2015

Pages